Pirfenidone : Anti-fibrotic agent with a potential therapeutic role in the management of transplantation patientsDOSANJH, Amrita.European journal of pharmacology. 2006, Vol 536, Num 3, pp 219-222, issn 0014-2999, 4 p.Article

Traitement de la fibrose pulmonaire idiopathique par pirfénidone: premiers retours d'expérience = Treatment of idiopathic pulmonary fibrosis with pirfenidone: preliminary lessonsWEMEAU-STERVINOU, L; TRACLET, J; BORIE, R et al.Revue des maladies respiratoires actualités (Print). 2012, Vol 4, issn 1877-1203, S26-S28, SUP1Article

Pirfenidone : A novel potential therapeutic agent in the management of chronic allograft rejectionDOSANJH, A.Transplantation proceedings. 2007, Vol 39, Num 7, pp 2153-2156, issn 0041-1345, 4 p.Conference Paper

A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisKING, Talmadge E; BRADFORD, Williamson Z; LEDERER, David J et al.The New England journal of medicine. 2014, Vol 370, Num 22, pp 2083-2092, issn 0028-4793, 10 p.Article

Pirfenidone: A Novel Agent for the Treatment of Idiopathic Pulmonary FibrosisPOTTS, Jason; YOGARATNAM, Dinesh.The Annals of pharmacotherapy. 2013, Vol 47, Num 3, pp 361-367, issn 1060-0280, 7 p.Article

Effects of Pirfenidone on Proliferation, Migration, and Collagen Contraction of Human Tenon's Fibroblasts In VitroXIANCHAI LIN; MINBIN YU; KAILI WU et al.Investigative ophthalmology & visual science. 2009, Vol 50, Num 8, pp 3763-3770, issn 0146-0404, 8 p.Article

Pharmacokinetics of an antifibrotic agent, pirfenidone, in haemodialysis patientsTANIYAMA, M; OHBAYASHI, S; NARITA, M et al.European journal of clinical pharmacology. 1997, Vol 52, Num 1, pp 77-78, issn 0031-6970Article

Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicitySHIHAB, Fuad S; BENNETT, William M; HONG YI et al.Transplantation. 2005, Vol 79, Num 4, pp 419-426, issn 0041-1337, 8 p.Article

Synthesis and structure-activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agentsJUN CHEN; LU, Miao-Miao; BIN LIU et al.Bioorganic & medicinal chemistry letters (Print). 2012, Vol 22, Num 6, pp 2300-2302, issn 0960-894X, 3 p.Article

Pirfenidone for Diabetic NephropathySHARMA, Kumar; IX, Joachim H; DONOHUE, Michael et al.Journal of the American Society of Nephrology. 2011, Vol 22, Num 6, pp 1144-1151, issn 1046-6673, 8 p.Article

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsNOBLE, Paul W; ALBERA, Carlo; VALEYRE, Dominique et al.Lancet (British edition). 2011, Vol 377, Num 9779, pp 1760-1769, issn 0140-6736, 10 p.Article

Pirfenidone in idiopathic pulmonary fibrosisTANIGUCHI, H; EBINA, M; TAKEUCHI, M et al.The European respiratory journal. 2010, Vol 35, Num 4, pp 821-829, issn 0903-1936, 9 p.Article

Pirfenidone Is Renoprotective in Diabetic Kidney DiseaseRAMACHANDRARAO, Satish P; YANQING ZHU; RAVASI, Timothy et al.Journal of the American Society of Nephrology. 2009, Vol 20, Num 8, pp 1765-1775, issn 1046-6673, 11 p.Article

Recent Advances in Molecular Targets and Treatment of Idiopathic Pulmonary Fibrosis : Focus on TGFβ Signaling and the MyofibroblastGHARAEE-KERMANI, M; HU, B; PHAN, S. H et al.Current medicinal chemistry. 2009, Vol 16, Num 11, pp 1400-1417, issn 0929-8673, 18 p.Article

Potent antioxidant role of Pirfenidone in experimental cirrhosisSALAZAR-MONTES, Adriana; RUIZ-CORRO, Luis; LOPEZ-REYES, Alberto et al.European journal of pharmacology. 2008, Vol 595, Num 1-3, pp 69-77, issn 0014-2999, 9 p.Article

Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromasBABOVIC-VUKSANOVIC, Dusica; WIDEMANN, Brigitte C; PACKER, Roger J et al.Pediatric neurology. 2007, Vol 36, Num 5, pp 293-300, issn 0887-8994, 8 p.Article

Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failureLEE, Ken W; EVERETT, Thomas H; RAHMUTULA, Dulkon et al.Circulation (New York, N.Y.). 2006, Vol 114, Num 16, pp 1703-1712, issn 0009-7322, 10 p.Article

Pirfenidone suppresses tumor necrosis factor-a, enhances interleukin-10 and protects mice from endotoxic shockOKU, Hisashi; NAKAZATO, Hitoshi; HORIKAWA, Tatsuya et al.European journal of pharmacology. 2002, Vol 446, Num 1-3, pp 167-176, issn 0014-2999Article

Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosisNAGAI, Sonoko; HAMADA, Kunio; SHIGEMATSU, Michio et al.Internal medicine (Tokyo. 1992). 2002, Vol 41, Num 12, pp 1118-1123, issn 0918-2918, 6 p.Article

A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasiaMESA, Ruben A; TEFFERI, Ayalew; HOOK, C. Christopher et al.British journal of haematology. 2001, Vol 114, Num 1, pp 111-113, issn 0007-1048Article

Renal collagen synthesis and its controlWARDLE, E. N.Nephron. 1999, Vol 83, Num 2, pp 106-110, issn 0028-2766Article

Pirfenidone for the treatment of idiopathic pulmonary fibrosisXAUBET, Antoni; SERRANO-MOLLAR, Anna; ANCOCHEA, Julio et al.Expert opinion on pharmacotherapy. 2014, Vol 15, Num 2, pp 275-281, issn 1465-6566, 7 p.Article

Pirfenidone Inhibits Pancreatic Cancer Desmoplasia by Regulating Stellate CellsKOZONO, Shingo; OHUCHIDA, Kenoki; EGUCHI, Daiki et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 7, pp 2345-2356, issn 0008-5472, 12 p.Article

The evolving pharmacotherapy of pulmonary fibrosisLOTA, Harpreet K; WELLS, Athol U.Expert opinion on pharmacotherapy. 2013, Vol 14, Num 1, pp 79-89, issn 1465-6566, 11 p.Article

Determination of Pirfenidone in Rat Plasma by LC-MS-MS and Its Application to a Pharmacokinetic StudySHUHUA TONG; XIANQIN WANG; HAIYAN JIANG et al.Chromatographia (Wiesbaden). 2010, Vol 71, Num 7-8, pp 709-713, issn 0009-5893, 5 p.Article